Clinical trials: Adjuvant Therapy for Bladder Cancer
Bladder Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00777491
- Testing
- induction cisplatin, induction 5-fluorouracil, induction gemcitabine
- Where
- 11 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Radiation Therapy Oncology Group
Biliary Tract Cancer
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
- Trial name
- NCT06109779
- Testing
- Rilvegostomig, Capecitabine, Gemcitabine/Cisplatin
- Where
- 176 sites in United States, Australia and 19 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Bladder Cancer
Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial
The objective of this prospective, single-center randomized controlled trial is to identify the optimal adjuvant intravesical therapy in patients with intermediate risk (IR) non muscle invasive bladder cancer by comparing two…
- Trial name
- NCT05146635
- Testing
- Intravesical Bcg, Intravesical chemotherapy (epirubicin)
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- Mansoura University
Bladder Cancer, Urethral Cancer
Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003701
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- 13 sites in United States
- Volunteers
- 490 people
- Sponsor
- Eastern Cooperative Oncology Group
Bladder Cancer
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy (RT) uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055601
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- Radiation Therapy Oncology Group
Bladder Cancer
Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer
Open label, randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer.
- Trial name
- BCG+MM (NCT02948543)
- Testing
- Bacillus of Calmette-Guerin (BCG), Mitomycin (MM)
- Where
- 17 sites in Australia, United Kingdom
- Volunteers
- 501 people
- Sponsor
- University of Sydney
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the DFS of TURBT followed by NDV-1 (sustained-release gemcitabine-docetaxel) versus TURBT followed by surveillance for the treatment of participants with…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder, Urologic Cancer
- Trial name
- BOOST (NCT07313891)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Sponsor
- Relmada Therapeutics, Inc.
Bladder Cancer
Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
This is a single-center, prospective, open-label, non-randomized clinical study initiated and conducted by the Department of Urology, Shanghai Changhai Hospital.
- Trial name
- MARINE-01 (NCT07307456)
- Testing
- Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Changhai Hospital
Bladder Cancer, Bladder Cancer Recurrence
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
Bladder cancer is a highly heterogeneous malignancy characterized by frequent genetic alterations that are closely associated with disease progression, recurrence risk, and treatment response.
- Conditions
- Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer, Progression of Bladder Cancer
- Trial name
- NCT07424560
- Testing
- Multiplex Mutation Detection System for Bladder Cancer (Nucleic Acid Mass Spectrometry)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhilong Dong
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant treatment following surgery in adult…
- Trial name
- PROOF302 (NCT04197986)
- Testing
- Infigratinib
- Where
- 143 sites in United States, Belgium and 9 more
- Volunteers
- 39 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Bladder (Urothelial, Transitional Cell) Cancer
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.
- Trial name
- NCT06696742
- Testing
- Clostridium Butyricum Tablets, Cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Urothelial Carcinoma Bladder, Bladder Cancer
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
- Trial name
- NCT06586255
- Testing
- Concurrent Immunotherapy and Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Muscle Invasive Bladder Cancer
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
- Trial name
- NIAGARA (NCT03732677)
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 1,063 people
- Sponsor
- AstraZeneca
Bladder Cancer, Carcinoma, Transitional Cell
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Primary Objective: To analyse time to tumor progression in patients cystectomized for locally advanced transitional cell carcinoma (TCC) of the bladder, who are not suitable for cisplatin-based chemotherapy (i.e.
- Trial name
- NCT00146276
- Testing
- gemcitabine
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Association of Urologic Oncology (AUO)
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
- Trial name
- NCT05987241
- Testing
- Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography
- Where
- 505 sites in United States, Canada
- Volunteers
- 992 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Bladder Cancer, Stage IV Bladder Cancer
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
This randomized phase II trial studies the side effects and how well postoperative intensity modulated radiotherapy works after surgery in treating patients with urothelial bladder cancer.
- Trial name
- NCT02316548
- Testing
- Intensity-Modulated Radiation Therapy
- Where
- 127 sites in United States, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- NRG Oncology
Non Muscle Invasive Bladder Cancer
Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT
This is a prospective, open-label, single-center, single-arm phase II clinical study to evaluate the efficacy and safety of toripalimab combined with intravesical gemcitabine as adjuvant therapy in patients with high-risk…
- Trial name
- NCT07808216
- Testing
- Toripalimab (JS001 ), Gemcitabine (GEM)
- Volunteers
- 54 people
- Sponsor
- Tianjin First Central Hospital
Urothelial Carcinoma of the Bladder
Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Invasive urothelial bladder cancer is a common malignancy causing 14,000 deaths annually in the United States. The primary objective of the feasibility/Phase I portion of the study is to establish the feasibility and safety of…
- Trial name
- NCT01520038
- Testing
- Proton therapy, IMRT
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Abramson Cancer Center at Penn Medicine